Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo

International Journal of Cancer

Volumn 130, Issue 2, 2012, Pages 454-466

  Urakawa, Hiroshi ^a   Nishida, Yoshihiro ^a   Wasa, Junji ^a   Arai, Eisuke ^a   Zhuo, Lisheng ^b   Kimata, Koji ^b   Kozawa, Eiji ^a   Futamura, Naohisa ^a   Ishiguro, Naoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

4 methylumbelliferone; bone destruction; bone metastasis; breast cancer; hyaluronan

Indexed keywords

CELL PROTEIN; HYALURONIC ACID; HYMECROMONE; MESSENGER RNA; PROTEIN HAS2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOGENICITY; CELL CYCLE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN 3T3; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD44; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CARTILAGE, ARTICULAR; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR MATRIX; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; HYMECROMONE; MICE; NIH 3T3 CELLS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; RNA, MESSENGER;

EID: 83655167411     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26014     Document Type: Article

References (50)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P,. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
2. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Murray T, Thun MJ,. Cancer statistics. CA Cancer J Clin 2008; 58: 71-96.
3. Mauri D, Pavlidis N, Ioannidis JPA,. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-94.
4. Manders K, van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJC, Nieuwenhuijzen GAP, Roumen RMH, Voogd AC,. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. Bmc Cancer 2006; 6: 8.
5. Coleman RE,. Skeletal complications of malignancy. Cancer 1997; 80: 1588-94.
6. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA,. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004; 42: 164-75.
7. Laurent TC, Fraser JRE,. Hyaluronan. FASEB J 1992; 6: 2397-404.
8. Toole BP,. Hyaluronan in morphogenesis. J Int Med 1997; 242: 35-40.
9. Chen WYJ, Abatangelo G,. Functions of hyaluronan in wound repair. Wound Repair Regen 1999; 7: 79-89.
10. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, Agren U, Alhava E, Kosma VM,. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998; 58: 342-7.
11. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM,. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000; 60: 150-5.
12. Auvinen PK, Parkkinen JJ, Johansson RT, Agren UM, Tammi RH, Eskelinen MJ, Kosma VM,. Expression of hyaluronan in benign and malignant breast lesions. Int J Cancer 1997; 74: 477-81.
13. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM,. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000; 156: 529-36.
14. Tabata I, Nishida Y, Sugiura H, Zhuo L, Yoneda M, Kimata K, Nakashima H, Ishiguro N,. A study of inter-alpha-trypsin inhibitor chains expression in liposarcomas. Eur J Surg Oncol 2003; 29: 665-9.
15. Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen JJ, Johansson R, Bohm J, Hollmen S, Kosma VM,. Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 2001; 95: 12-7.
16. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U, Kosma VM,. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 2001; 37: 849-56.
17. Knudson W, Biswas C, Toole BP,. Interactions between human-tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci USA 1984; 81: 6767-71.
18. Asplund T, Versnel MA, Laurent TC, Heldin P,. Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial Cells and fibroblasts. Cancer Res 1993; 53: 388-92.
19. Kimata K, Honma Y, Okayama M, Oguri K, Hozumi M, Suzuki S,. Increased synthesis of hyaluronic-acid by mouse mammary-carcinoma cell variants with high metastatic potential. Cancer Res 1983; 43: 1347-54.
20. Udabage L, Brownlee GR, Nilsson SK, Brown TJ,. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res 2005; 310: 205-17.
21. Itano N, Sawai T, Yoshida M, Lenas P, Yamada Y, Imagawa M, Shinomura T, Hamaguchi M, Yoshida Y, Ohnuki Y, Miyauchi S, Spicer AP, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999; 274: 25085-92.
22. Kosaki R, Watanabe K, Yamaguchi Y,. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 1999; 59: 1141-5.
23. Ichikawa T, Itano N, Sawai T, Kimata K, Koganehira Y, Saida T, Taniguchi S,. Increased synthesis of hyaluronate enhances motility of human melanoma cells. J Invest Dermatol 1999; 113: 935-9.
24. Kim HR, Wheeler MA, Wilson CM, Iida J, Eng D, Simpson MA, McCarthy JB, Bullard KM,. Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res 2004; 64: 4569-76.
25. Nishida Y, Knudson W, Knudson CB, Ishiguro N,. Antisense inhibition of hyaluronan synthase-2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp Cell Res 2005; 307: 194-203.
26. Simpson MA, Wilson CM, McCarthy JB,. Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 2002; 161: 849-57.
27. Golshani R, Lopez L, Estrella V, Kramer M, Lida N, Lokeshwar VB,. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 2008; 68: 483-91.
28. Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, Nilsson SK, Thompson EW, Brown TJ,. Anti sense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 2005; 65: 6139-50.
29. Li YJ, Li LL, Brown TJ, Heldin P,. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer 2007; 120: 2557-67.
30. Kakizaki I, Kojima K, Takagaki K, Endo M, Kannagi R, Ito M, Maruo Y, Sato H, Yasuda T, Mita S, Kimata K, Itano N,. A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem 2004; 279: 33281-9.
31. Vigetti D, Rizzi M, Viola M, Karousou E, Genasetti A, Clerici M, Bartolini B, Hascall VC, De Luca G, Passi A,. The effects of 4-methylumbelliferone on hyaluronan synthesis, MMP2 activity, proliferation, and motility of human aortic smooth muscle cells. Glycobiology 2009; 19: 537-46.
32. Kultti A, Pasonen-Seppanen S, Jauhiainen M, Rilla KJ, Karna R, Pyoria E, Tammi RH, Tammi MI,. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res 2009; 315: 1914-23.
33. Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N, Altman N,. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res 2010; 70: 2613-23.
34. Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J, Nagy P,. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007; 43: 2423-33.
35. Tammi R, Rilla K, Pienimaki JP, MacCallum DK, Hogg M, Luukkonen M, Hascall VC, Tammi M,. Hyaluronan enters keratinocytes by a novel endocytic route catabolism. J Biol Chem 2001; 276: 35111-22.
36. Zhu L, Zhuo LS, Kimata K, Yamaguchi E, Watanabe H, Aronica MA, Hascall VC, Baba K,. Deficiency in the serum-derived hyaluronan-associated protein-hyaluronan complex enhances airway hyperresponsiveness in a murine model of asthma. Int Arch Allergy Immunol 2010; 153: 223-33.
37. Bourguignon LYW, Singleton PA, Zhu HB, Diedrich F,. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (Macrophage-Colony stimulating factor) production and breast tumor progression. J Biol Chem 2003; 278: 29420-34.
38. Russo RIC, Garcia MG, Alaniz L, Blanco G, Alvarez E, Hajos SE,. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 2008; 122: 1012-8.
39. Twarock S, Tammi M, Savani R, Fischer J,. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem 2010; 285: 23276-84.
40. Hosono K, Nishida Y, Knudson W, Knudson CB, Naruse T, Suzuki Y, Ishiguro N,. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol 2007; 171: 274-86.
41. Suzuki Y, Nishida Y, Naruse T, Gemba T, Ishiguro N,. Pericellular matrix formation alters the efficiency of intracellular uptake of oligonucleotides in osteosarcoma cells. J Surg Res 2009; 152: 148-56.
42. Evanko SP, Wight TN,. Intracellular localization of hyaluronan in proliferating cells. J Histochem Cytochem 1999; 47: 1331-41.
43. Knudson W, Chow G, Knudson CB,. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol 2002; 21: 15-23.
44. Turley EA, Noble PW, Bourguignon LYW,. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277: 4589-92.
45. Rilla K, Pasonen-Seppanen S, Rieppo J, Tammi M, Tammi R,. The hyaluronan synthesis inhibitor 4-methylumbelliferone prevents keratinocyte activation and epidermal hyperproliferation induced by epidermal growth factor. J Invest Dermatol 2004; 123: 708-14.
46. Rilla K, Lammi MJ, Sironen R, Torronen K, Luukkonen M, Hascall VC, Midura RJ, Hyttinen M, Pelkonen J, Tammi M, Tammi R,. Changed lamellipodial extension, adhesion plaques and migration in epidermal keratinocytes containing constitutively expressed sense and antisense hyaluronan synthase 2 (Has2) genes. J Cell Sci 2002; 115: 3633-43.
47. Bourguignon LYW,. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 2008; 18: 251-9.
48. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J, Turley EA,. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007; 282: 16667-80.
49. Edward M, Quinn J, Pasonen-Seppänen S, McCann B, Tammi R,. 4-Methylumbelliferone inhibits tumour cell growth and the activation of stromal hyaluronan synthesis by melanoma cell-derived factors. Br J Dermatol 2010; 162: 1224-32.
50. Kobayashi N, Miyoshi S, Mikami T, Koyama H, Kitazawa M, Takeoka M, Sano K, Amano J, Isogai Z, Niida S, Oguri K, Okayama M, et al. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res 2010; 70: 7073-83.